A randomized, double-blind, parallel-group, fixed-dose, clinical trial of quetiapine at 600 versus 1200 mg/d for patients with treatment-resistant schizophrenia or schizoaffective disorder

Journal of Clinical Psychopharmacology

Volumn 31, Issue 2, 2011, Pages 160-168

  Lindenmayer, Jean Pierre ^a,b,c   Citrome, Leslie ^b,c   Khan, Anzalee ^a,d   Kaushik, Sashank ^e   Kaushik, Saurabh ^a,c  

^a MANHATTAN PSYCHIATRIC CENTER   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d FORDHAM UNIVERSITY   (United States)

^e BROOKDALE UNIVERSITY HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

high dose quetiapine; treatment resistant schizophrenia

Indexed keywords

ARIPIPRAZOLE; CHLORPROMAZINE; CREATINE KINASE; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; HEMOGLOBIN; LIVER ENZYME; MOLINDONE; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; THYROTROPIN; TIOTIXENE; TRIACYLGLYCEROL; ZIPRASIDONE;

ADULT; AGITATION; ARTICLE; BEDTIME DOSAGE; CATARACT; CONSTIPATION; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MENTAL HEALTH CENTER; MORNING DOSAGE; MULTICENTER STUDY; NEUTROPHIL COUNT; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; PARALLEL DESIGN; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ADULT; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 79952448634     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/JCP.0b013e31820f4fe0     Document Type: Article

References (24)

1. Emsley RA, Raniwalla J, Bailey PJ, et al. A comparison of the effects of quetiapine ('seroquel') and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. PRIZE Study Group. Int Clin Psychopharmacol. 2000;15:121-131. (Pubitemid 30326047)
2. Citrome L, Jaffe A, Levine J, et al. Dosing of quetiapine in schizophreniaVhow clinical practice differs from registration studies. J Clin Psychiatry. 2005;66:1512-1516. (Pubitemid 43068688)
3. Reinstein MJ, Sonnenberg JG, Chasanov MA, et al. Comparative efficacy and tolerability of quetiapine at high and low doses. New Research Poster NR353, 154th Annual Meeting of the American Psychiatric Association, New Orleans, LA, 5-10 May 2001.
4. Nagy J. Efficacy, safety and tolerability of quetiapine: short-term high doses with long-term follow-up. Int J Psychiatry Clin Pract. 2005;9:16-21. (Pubitemid 40363637)
5. Pierre JM, Rivard JM, Marks R, et al. High dose quetiapine in treatment refractory schizophrenia. Schizophr Res. 2005;73:373-375. (Pubitemid 40093903)
6. Boggs DL, Kelly DL, Feldman S, et al. Quetiapine at high doses for the treatment of refractory schizophrenia. Schizophr Res. 2008;101:347-348.
7. MacEwan GW, Honer WG. A Canadian, Multicentre, Double-Blind, Randomized, Parallel-Group Study of the Safety, Tolerability, and Efficacy of Treatment with Higher Doses of Quetiapine Fumarate (Seroquel\) greater than 800 mg/day in Schizophrenic or Schizoaffective Subjects. Astra Zeneca Document No. CNS.000-105-629. 30 November 2006. Available at: http://www. astrazenecaclinicaltrials. com/-mshost800325/content/clinical-trials/resources/ pdf/9256895. Accessed November 2, 2010.
8. Honer W, Macewan G, Gendron A, et al. A double blind, placebo controlled study of the safety and tolerability of quetiapine 1200 mg/d versus 800 mg/d in patients with persistent symptoms of schizophrenia or schizoaffective disorder. Schizophr Res. 2010;117:375.
9. Dragicevic A, Sachse J, Härtter S, et al. Serum concentrations of quetiapine and clinical effects. Pharmacopsychiatry. 2005;38:47-48.
10. Mossman D, Somoza E. ROC curves, test accuracy, and the description of diagnostic tests. J Neuropsychiatry Clin Neurosci. 1991;3:330-333.
11. Swift RH, Harrigan EP, Cappelleri JC, et al. Validation of the Behavioral Activity Rating Scale (BARS): a novel measure of activity in agitated patients. J Psychiatr Res. 2002;36:87-95. (Pubitemid 34007608)
12. Kay SR, Fiszbein A, Opler LA. The Positive And Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261-276. (Pubitemid 18039085)
13. Harvey PD, Davidson M, Mueser KT, et al. Social-Adaptive Functioning Evaluation (SAFE): a rating scale for geriatric psychiatric patients. Schizophr Bull. 1997;23:131-145. (Pubitemid 27087913)
14. Lindenmayer JP, Bernstein-Hyman R, Grochowski S, et al. Psychopathology of schizophrenia: initial validation of a 5-factor model. Psychopathology. 1995;28(1):22-31. (Pubitemid 24368666)
15. Meltzer HY. Massive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message? Psychopharmacology. 2000;150:349-350. (Pubitemid 30447856)
16. Meltzer HY. Serum creatine phosphokinase in schizophrenia. Am J Psychiatry. 1976;133:192-197.
17. Meltzer HY, Cola PA, Parsa M. Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology. 1996;15:395-405. (Pubitemid 26342923)
18. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 1999;21:106S-115S. (Pubitemid 29396478)
19. Hajduch E, Dombrowski L, Darakhshan F, et al. Biochemical localisation of the 5-HT2A (serotonin) receptor in rat skeletal muscle. Biochem Biophys Res Commun. 1999;257(2):369-372. (Pubitemid 29301451)
20. Gortney JS, Fagan A, Kissack JC. Neuroleptic malignant syndrome secondary to quetiapine. Ann Pharmacother. 2009;43:785-791.
21. Bachmann CJ, Nicksch B, de Lange D, et al. Repeated creatine kinase elevation under treatment with quetiapine, clozapine, and aripiprazole in an adolescent. J Clin Psychopharmacol. 2007;27:710-711. (Pubitemid 351339463)
22. Plesnicar BK, Lasic JK, Plesnicar A. Quetiapine and elevated creatine phosphokinase (CK). Pharmacopsychiatry. 2007;40:203-204.
23. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia. Arch Gen Psychiatry. 2000;57(6):553-559.
24. Meltzer HY. Duration of a clozapine trial in neuroleptic-resistant schizophrenia. Arch Gen Psychiatry. 1990;47:290-291.